m.eriksen

TL2 · Lublin

Contributes reviews on supplier material. Based in Lublin.

Joined 23 July 2025 · last posted 2d

64 posts, newest first. Showing up to 150.

Publication patterns in the BPC-157 literature, examined Replied, post #45 · Compounds › Repair & healing peptides · 26 Jul 2026 · 3 likes If someone has run publication patterns properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #97 · Practice › Dosing & titration · 25 Jul 2026 · 0 likes Everything in post #93 holds. The case it does not cover is the one I have. Dose equivalence between different incretin analogues is a weak concept. The molecules…
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #10 · Clinical › Bloodwork · 17 Jul 2026 · 4 likes Taking post #7 at face value and following it one step further. What I want from this egfr fluctuation thread is the list of things that would need to be true for the…
Common supplements people ask about, assessed one at a time Replied, post #58 · Practice › Interactions · 17 Jul 2026 · 1 like I read post #55 twice before replying, because I had assumed the opposite. Filing a mild objection to the consensus on common supplements. Mild because I might be…
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #35 · Compounds › Repair & healing peptides · 16 Jul 2026 · 0 likes Useful. I had the fact and not the reason, which turns out to be the important half.
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #84 · Analytics › Home & field testing · 14 Jul 2026 · 9 likes Checked the consumer-accessible tests claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #67 · Analytics › Home & field testing · 9 Jul 2026 · 1 like Where I part company with post #65, and it is a narrow parting. Enzyme assays: if you have an enzyme that reacts specifically with your compound, an enzyme-based assay…
Mass error in ppm: the arithmetic and the caveat — a second dataset Replied, post #17 · Analytics › Mass spectrometry · 7 Jul 2026 · 8 likes Common adducts: sodium adds ≈22, potassium adds ≈38 compared to hydrogen. A [M+Na]+ peak is common and its mass is predictable from the base mass. Not a conclusion. A…
A structured critique template this community uses — a second dataset Replied, post #28 · Evidence › Study critique · 4 Jul 2026 · 0 likes Worth separating two things that post #26 runs together. What I want from this structured critique template thread is the list of things that would need to be true for…
Request: tag synonyms surfaced in search Replied, post #8 · Meta › Feature requests · 29 Jun 2026 · 0 likes Request with the use case rather than the feature. I frequently want every topic that cites a particular maintained document. At the moment I can find the document from…
Alcohol: what is documented and what is folklore Replied, post #82 · Practice › Interactions · 28 Jun 2026 · 11 likes That matches what I have seen, for whatever a single anecdote is worth.
Pooling trials with different estimands Replied, post #5 · Evidence › Meta-analyses · 3 Jun 2026 · 25 likes This follows post #2 rather than contradicting it. Nobody has said the unglamorous part of pooling trials with different estimands yet, so: most of the variation is…
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #4 · Practice › Storage & stability · 31 May 2026 · 5 likes The confident answers on reconstituted and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #30 · Practice › Reconstitution · 30 Apr 2026 · 0 likes Narrowing post #29, because the general version has more than one answer. Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither…
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #116 · Pharmacology › Pharmacokinetics · 23 Apr 2026 · 33 likes Clear enough that I do not think I have a follow-up, which is unusual.
Prescription portability between countries Replied, post #8 · Access › International · 14 Apr 2026 · 2 likes Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more…
Follow-up: Sleep quality changes during weight loss Replied, post #4 · Wellbeing › Sleep · 13 Apr 2026 · 2 likes Right — I had this wrong and I am glad to have read it before it mattered.
Completing a dose with a second syringe, and the dead-volume arithmetic Replied, post #25 · Practice › Administration · 9 Apr 2026 · 9 likes Building on post #22 rather than restating it. A genuinely late dose: the labelling generally says that if the next dose is more than a couple of days away, take it as…
Revisiting: Drawing up with one needle and injecting with another Replied, post #80 · Practice › Administration · 8 Apr 2026 · 17 likes Pinch or no pinch: the decision depends on needle length and on your own anatomy. A longer needle (8 mm and up) reaches subcutaneous tissue easily without a pinch. A…
Spike-and-recover accuracy for a peptide assay Replied, post #22 · Analytics › Method validation · 7 Apr 2026 · 0 likes Coming back to post #20, because the follow-up matters more than the original answer. Validation is compound-specific and matrix-specific. A method validated for one…
Second pass at: Choosing a concentration on purpose rather than by accident Replied, post #49 · Practice › Reconstitution · 20 Mar 2026 · 8 likes On post #47 — agreed on the reasoning, with one qualification. Worked example, since the arithmetic is the whole question. Five milligrams into one millilitre is 5…
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #52 · Outcomes › Progress reports · 14 Feb 2026 · 8 likes The arithmetic in post #51 is right; the assumption feeding it is the part to check. Summarising the Seven-day rolling thread so far, since it is long and the answer is…
Anxiety in the first weeks: drug, situation, or both — what changed since Replied, post #87 · Wellbeing › Mental health · 6 Feb 2026 · 2 likes Social and relationship impacts: weight change affects how others perceive and interact with a person. Those impacts are real and can be psychologically significant. I…
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #37 · Sourcing › Red flags · 4 Jan 2026 · 26 likes Documentation quality as a signal: a supplier that reports method identifiers, distinguishes specification from result, and states the counter-ion form is telling you…
Oral semaglutide bioavailability and its variability between people Replied, post #21 · Compounds › Oral incretins · 15 Dec 2025 · 12 likes Adding a data point of agreement rather than a data point.
Robustness: the parameters worth deliberately varying Replied, post #39 · Analytics › Method validation · 3 Dec 2025 · 6 likes Robustness has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
Coming back to: Feature request: should a dose-equivalence tool exist at all? Replied, post #23 · Data & Tools › Calculators · 30 Nov 2025 · 26 likes If a tool asks for a value you do not have, the honest response is to find the value rather than to estimate it. Estimated inputs propagate silently.
Coming back to: Injection-site reactions: describing them precisely enough to be useful Replied, post #9 · Practice › Side effects · 22 Nov 2025 · 3 likes On Injection-site reactions: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any…
Thyroid function tests during substantial weight change Replied, post #123 · Clinical › Bloodwork · 5 Nov 2025 · 1 like Analytical imprecision: any measurement has an error margin. A small difference in consecutive tests is usually measurement noise, not a real change. Knowing the…
How to read a phase 2 result without treating it as a phase 3 result — what changed since Replied, post #12 · Compounds › Retatrutide · 27 Oct 2025 · 20 likes Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early…
Publishing an inconvenient result: a case study — the long version Replied, post #6 · Sourcing › Independent verification · 9 Oct 2025 · 0 likes Taking post #5 at face value and following it one step further. A note on scope: what I am saying about Publishing an inconvenient result applies to the case in the…
What a purity-only report leaves out Replied, post #24 · Sourcing › Independent verification · 24 Sep 2025 · 0 likes Worth stating the null on purity-only before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
Aggregated purity results across four services, with caveats — a second dataset Replied, post #55 · Data & Tools › Datasets · 8 Sep 2025 · 25 likes Where a dataset is used to support a claim in a maintained document, the version used should be cited. Otherwise the document and the data drift apart silently.
Confounding by indication, explained with a concrete example Replied, post #7 · Evidence › Study critique · 31 Aug 2025 · 3 likes Per-protocol and intention-to-treat analyses answer different questions and neither is the honest one by default. Reporting both is the practice worth insisting on.
Revisiting: List price versus negotiated price versus what you pay Replied, post #29 · Access › Pricing · 11 Aug 2025 · 12 likes Useful. I have added it to my own notes with the date on it.
Coming back to: What published stability data actually covers, and what it does not Replied, post #88 · Practice › Storage & stability · 16 Jul 2025 · 0 likes Visible particulate is a strong signal in the other direction: it is a reason to stop and ask rather than to filter and proceed. If that reads as pedantic, it is, and…
Journal club: the CagriSema phase 2 combination paper — a second dataset Replied, post #21 · Evidence › Journal club · 31 May 2025 · 2 likes Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything…
[2026 update] Clearance pathways and what renal impairment changes Replied, post #13 · Pharmacology › Pharmacokinetics · 24 May 2025 · 5 likes This settles it for me, at least until somebody posts a reason it should not.
Follow-up: Documentation that appears only after payment Replied, post #71 · Sourcing › Red flags · 12 May 2025 · 3 likes Exaggerated claims without documentation: every compound has limits. No peptide is "100% pure" because purity is measured to finite precision. A supplier claiming…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #77 · Compounds › Tirzepatide · 5 May 2025 · 4 likes I would put moderate confidence on the mainstream reading of tirzepatide in type 2 diabetes and no more. That is not scepticism for its own sake; it is where the…
Reporting a disappointing outcome, and why it belongs here Replied, post #10 · Outcomes › Progress reports · 15 Apr 2025 · 10 likes Second-hand on reporting a disappointing outcome, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Follow-up: What other technical communities get right that we do not Replied, post #51 · Lounge › Off topic · 28 Mar 2025 · 29 likes Non-technical and offered in the right category: the best thing about a forum with no vote score is that the boring accurate answer sits at the same level as the…
Why one laboratory's 98.4% and another's 96.1% may not contradict Replied, post #2 · Analytics › Method validation · 27 Mar 2025 · 0 likes Following this. I have the same question and no better information than the first post.
Why cagrilintide alone is discussed so much less than in combination Started this topic · Compounds › Cagrilintide & amylin analogues · 20 Mar 2025 · 18 likes Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below.…
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #105 · Access › International · 17 Mar 2025 · 20 likes I read post #102 twice before replying, because I had assumed the opposite. Nobody has said the unglamorous part of Cross-border purchase within yet, so: most of the…
Maintainer handover: how it works Replied, post #37 · Meta › Wiki maintenance · 15 Mar 2025 · 3 likes I read post #34 twice before replying, because I had assumed the opposite. That matches how I use it. The general statement is what you check afterwards, not what you…
Validating a method you did not develop — does this still hold? Replied, post #44 · Analytics › Method validation · 25 Feb 2025 · 0 likes Specificity is the first question: does the method separate the analyte from everything reasonably expected to be present? A method that has not been challenged with…
Talking to a therapist about this specifically — does this still hold? Replied, post #15 · Wellbeing › Mental health · 9 Feb 2025 · 0 likes Sensible. I would want the same detail before I acted on it either.
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #21 · Practice › Reconstitution · 27 Jan 2025 · 0 likes Reconstituting a multi-strength kit: if a kit contains 5 mg, 10 mg, 15 mg vials and you are reconstituting all of them, writing the concentration on each vial in…
The topic list is dense — is that deliberate? Replied, post #82 · Meta › Site feedback · 13 Jan 2025 · 21 likes Same experience here, different supplier, so it is at least not unique to one of them.
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #49 · Compounds › Semaglutide · 28 Dec 2024 · 8 likes I will take the caveat as seriously as the claim, which is the point of putting it there.
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #72 · Evidence › Journal club · 26 Dec 2024 · 32 likes I had written a reply contradicting post #70 and deleted it. Here is what survived. PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not…
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #38 · Compounds › Cagrilintide & amylin analogues · 20 Dec 2024 · 9 likes Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate…
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #7 · Compounds › Semaglutide · 18 Dec 2024 · 0 likes Picking up post #4: that is the part I would want checked first. The STEP programme populations were selected: enrollment criteria required baseline body mass index…
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #91 · Compounds › Tirzepatide · 16 Dec 2024 · 15 likes On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent…
Gallbladder disease risk with rapid weight loss Replied, post #39 · Clinical › Comorbidities · 4 Dec 2024 · 22 likes Post #35 describes the usual case. This is about the unusual one. The question underneath gallbladder disease risk is usually "how would I tell?" rather than "what is…
Time to steady state after a dose increase Replied, post #13 · Pharmacology › Pharmacokinetics · 2 Nov 2024 · 0 likes Agreed, and I will stop repeating the version of this I had been repeating.
[2026 update] Step therapy requirements and how to satisfy them Replied, post #7 · Access › Insurance & coverage · 28 Oct 2024 · 0 likes Where I part company with post #5, and it is a narrow parting. Step therapy requirements is one of those subjects where the general answer and the answer for a specific…
When a red flag was a misunderstanding, and the retraction Replied, post #33 · Sourcing › Red flags · 13 Oct 2024 · 25 likes I had read the opposite somewhere and cannot now find where, which tells me something.
Circumference measurements as a poor man's composition estimate Replied, post #35 · Outcomes › Body composition · 2 Aug 2024 · 16 likes Maintenance phase: tracking body composition during maintenance (weight stable) is different from tracking during active loss. Changes are smaller and precision becomes…
Guidelines revision: what changed and why Replied, post #88 · Meta › Announcements · 27 Jul 2024 · 1 like Narrowing post #87, because the general version has more than one answer. The edit is clearer. For anyone arriving now, read the edited version — the confusion in the…
Guidelines revision: what changed and why Replied, post #63 · Meta › Announcements · 26 Jul 2024 · 0 likes Thank you for announcing it in advance rather than after. The number of places that do the reverse is remarkable.
How to ask for a dose change without antagonising anyone Replied, post #4 · Clinical › Prescriber conversations · 9 Jul 2024 · 16 likes Nothing here is medical advice, and this subcategory exists to help people ask better questions rather than to answer them. The variance between people here is larger…
Units, standards, and other things that quietly hold the world together — one year on Started this topic · Lounge › Off topic · 27 Jun 2024 · 50 likes On the subject in the title: Units, standards, and other things that quietly hold the world together — one year on Working notes rather than a conclusion. Two things I…